Susceptibility genes in Graves' ophthalmopathy: searching for a needle in a haystack?

被引:64
作者
Bednarczuk, Tomasz
Gopinath, Bamini
Ploski, Rafal
Wall, Jack R.
机构
[1] Univ Sydney, Western Clin Sch, Nepean Hosp, Dept Med, Penrith, NSW 2751, Australia
[2] Med Univ Warsaw, Dept Endocrinol, Warsaw, Poland
[3] Polish Acad Sci, Dept Endocrinol, Med Res Ctr, Warsaw, Poland
[4] Med Univ Warsaw, Dept Med Genet, Warsaw, Poland
关键词
D O I
10.1111/j.1365-2265.2007.02854.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The variety of clinical presentations of eye changes in patients with Graves' disease suggests that complex interactions between genetic, environmental, endogenous and local factors influence the development/severity of Graves' ophthalmopathy (GO). At present, the role of genetic factors in the development of GO remains unknown. Based on small case-control association studies with candidate genes, several susceptibility loci in GO have been proposed. These are human leucocyte antigen (HLA, 6p21.3), cytotoxic T-lymphocyte antigen-4 (CTLA-4, 2q33), tumour necrosis factor (TNF, 6p21.3), interferon-gamma (IFN-gamma, 12q14), intercellular adhesion molecule-1 (ICAM-1, 19p13), and thyroid stimulating hormone receptor gene (TSH-R, 14q31). Unfortunately, these results were either not confirmed or require replication in larger studies. There are many reasons for the lack of reproducibility of association studies in GO, including poor characterization of the studied groups and small sample sizes, which may result in both false positive and negative results. Thus, the genetic background of GO remains to be elucidated in future research. However, the possibility that GO may be a genetically heterogeneous disorder, or that the development of GO may be predominantly influenced by environmental factors such as cigarette smoking, can not be disregarded.
引用
收藏
页码:3 / 19
页数:17
相关论文
共 136 条
[91]   Quantitative synthesis in systematic reviews [J].
Lau, J ;
Ioannidis, JPA ;
Schmid, CH .
ANNALS OF INTERNAL MEDICINE, 1997, 127 (09) :820-826
[92]   HLA class II associations in juvenile Graves' disease: indication of a strong protective role of the DRB1*0701,DQA1*0201 haplotype [J].
Lavard, L ;
Madsen, HO ;
Perrild, H ;
Jacobsen, BB ;
Svejgaard, A .
TISSUE ANTIGENS, 1997, 50 (06) :639-641
[93]   Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease [J].
Lohmueller, KE ;
Pearce, CL ;
Pike, M ;
Lander, ES ;
Hirschhorn, JN .
NATURE GENETICS, 2003, 33 (02) :177-182
[94]  
MANJI N, J CLIN ENDOCRINOLOGY, V91, P4873
[95]   Glycosaminoglycans provide a binding site for thyroglobulin in orbital tissues of patients with thyroid-associated ophthalmopathy [J].
Marinò, M ;
Lisi, S ;
Pinchera, A ;
Marcocci, C ;
Menconi, F ;
Morabito, E ;
Macchia, M ;
Sellari-Franceschini, S ;
McCluskey, RT ;
Chiovato, L .
THYROID, 2003, 13 (09) :851-859
[96]  
Marsh S G E, 2003, Tissue Antigens, V61, P410, DOI 10.1034/j.1399-0039.2003.00051.x
[97]   Lack of association of Graves' disease with the A2 allele of the interleukin-1 receptor antagonist gene in a white European population [J].
Mühlberg, T ;
Kirchberger, M ;
Spitzweg, C ;
Herrmann, F ;
Heberling, HJ ;
Heufelder, AE .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 1998, 138 (06) :686-690
[98]   Lack of association of interleukin-18 gene polymorphisms with susceptibility of Japanese populations to Graves' disease or Graves' ophthalmopathy [J].
Mukai, T ;
Hiromatsu, Y ;
Ichimura, M ;
Fukutani, T ;
Kaku, H ;
Miyake, I ;
Shoji, S ;
Koda, Y ;
Bednarczuk, T .
THYROID, 2006, 16 (03) :243-248
[99]   A C/T polymorphism in the 5′ untranslated region of the CD40 gene is associated with later onset of Graves' disease in Japanese [J].
Mukai, T ;
Hiromatsu, Y ;
Fukutani, T ;
Ichimura, M ;
Kaku, H ;
Miyake, I ;
Yamada, K .
ENDOCRINE JOURNAL, 2005, 52 (04) :471-477
[100]   Mechanisms of MHC class I - Restricted antigen processing [J].
Pamer, E ;
Cresswell, P .
ANNUAL REVIEW OF IMMUNOLOGY, 1998, 16 :323-358